On September 23, 2026 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, reported that they will provide new data for Lu-edotreotide (ITM-11) in two poster presentations at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, held from September 26 – 30, 2026 in Boston, Massachusetts. One poster will feature Phase 3 COMPETE trial dosimetry results for 177Lu-edotreotide in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A second poster will highlight findings from a registry analysis of re-treatment with 177Lu-edotreotide in patients with progressive neuroendocrine tumors (NETs).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation Details
Title: 177Lu-edotreotide Absorbed Dose in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Dosimetry Results from COMPETE
Abstract Number: 2100
Poster Board Number: 27
Poster Session: PQA 01: Gastrointestinal Cancer and Central Nervous System
Date and Time: Sunday, September 27, 2026, 3:00 – 4:00 PM ET
Location: Poster Hall – Exhibit Hall A
Presenter: Dr. Amir Iravani, University of California, Los Angeles, California
Title: Re-treatment with 177Lu-edotreotide in patients with progressive NETs: a SwissNet Registry
Abstract Number: 2066
Poster Board Number: 27
Poster Session: PQA 01: Gastrointestinal Cancer and Central Nervous System
Date and Time: Sunday, September 27, 2026, 3:00 – 4:00 PM ET
Location: Poster Hall – Exhibit Hall A
Presenter: Dr. Julia G. Fricke, University Hospital Basel, Basel, Switzerland
About the COMPETE Trial
The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs.
(Press release, ITM Isotopen Technologien Munchen, SEP 23, 2026, View Source [SID1234671042])